Results 181 to 190 of about 76,618 (225)

The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study. [PDF]

J Cosmet Dermatol
Gupta AK, Bamimore MA, Wang T, Talukder M.   +3 more
europepmc   +1 more source

Safety profile of TNF- alpha Inhibitors in pediatric patients: A post-marketing surveillance study based on the FAERS database. [PDF]

PLoS One
Yang Y, Wang P, Li QX.
europepmc   +1 more source

The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases - psoriasis and atopic dermatitis. [PDF]

Ann Med
Lemiesz P, Nowowiejska-Purpurowicz J, Flisiak I.   +2 more
europepmc   +1 more source

Modelling the cost effectiveness of TNF-α inhibitors in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry [PDF]

Bansback, N., Brennan, A., Nixon, R.
core  

Some of the next articles are maybe not open access.

Related searches:

Etanercept

Expert Opinion on Biological Therapy, 2008
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease.
Erin, Ducharme, Jeffrey M, Weinberg
  +6 more sources

Etanercept

BioDrugs, 2004
Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFalpha and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in
Paul L, McCormack, Keri, Wellington
openaire   +2 more sources